Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Zenapax (Daclizumab) for the Prevention of Primary Acute Cardiac Rejection in Children and Adolescents. Ind Number: 10100

NCT00284531 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT00284531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00284531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Zenapax (Daclizumab) for the Prevention of Primary Acute Cardiac Rejection in Children and Adolescents. Ind Number: 10100
Lead sponsor
Baylor College of Medicine
Phase
Phase 1/2
Overall status
Terminated
Start date
October 31, 2003
Completion date
May 31, 2007
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac transplantation